ClinicalTrials.gg
Status unknownNCT00450593Updated Aug 12, 2013

Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma

An observational study in Hereditary Multiple Melanoma and Melanoma (Skin), sponsored by Leeds Cancer Centre at St. James's University Hospital. Status unknown at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2013-08-12.

Sponsored by Leeds Cancer Centre at St. James's University Hospital · Observational

The sponsor has not verified this record recently (last verified Apr 2008), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Enrollment
5,000
Sex
All
01

Study summary

RATIONALE: Identifying gene mutations and other risk factors in patients with melanoma and in families with a history of hereditary melanoma may help doctors identify persons at risk for melanoma and other types of cancer. It may also help the study of cancer in the future.

PURPOSE: This clinical trial is studying gene mutations in patients with melanoma and in families with a history of hereditary melanoma.

Read the detailed description

OBJECTIVES:

  • Determine the incidence and etiologic significance of variants of known melanoma susceptibility genes (MSGs) in families with multiple cases of melanoma.
  • Determine the proportion of multiple-case families that are explained by high-penetrance mutations in known MSGs.
  • Determine the proportion of multiple-case families that are explained by these mutations and whether it varies with latitude, as a surrogate for ultraviolet exposure, with number of affected relatives, with average age at onset of melanoma in relatives, with presence of multiple primary melanoma, or with other family-specific variables.
  • Determine the penetrance of MSG mutations in these families.
  • Determine if the penetrance varies with age, sex, or birth cohort.
  • Determine if the penetrance varies with the gene involved or nature of the mutation.
  • Assess the penetrance in mutations that also have a deleterious effect on the alternative splice product, p14ARF.
  • Determine whether carriers of MSGs have an increased susceptibility to other types of cancer.
  • Determine the risk of other types of cancers for mutation carriers.
  • Determine environmental exposures, in particular sun exposure, that modify risk of melanoma in MSG mutation carriers.
  • Determine the cutaneous phenotypes that correlate with melanoma risk in these families.
  • Correlate cutaneous phenotypes with the presence of MSG variants.
  • Determine the effect of other covariates, such as sun exposure or the presence of alleles of putative modifying genes (e.g., MC1R or CDKN2A), on phenotype.
  • Determine if modifier genes, such as those controlling pigmentation of the skin, and therefore sun susceptibility, modify risk in MSG mutation carriers.
  • Identify any histopathological correlates of MSG status in primary tumors arising in melanoma-susceptible individuals in these families.
  • Identify any histopathological correlates of primary melanomas in carriers of MSG mutations with other covariates.

OUTLINE: This is a case-control, multicenter study.

Participants complete 2 questionnaires and assist in the creation and expansion of a family pedigree. Blood samples are examined for melanoma susceptibility gene mutations, including CDK4 and CDKN2A.

Participants are also examined for moles and photographed. Physical variables (e.g., skin, eye, and hair pigmentation) and sun damage (solar lentigines and freckling) are also noted.

If available, tissue samples are examined for Clark level, Breslow thickness, and frequency of mitoses. Peri-lesional skin from tumors is examined by p53 staining.

Participants are followed periodically to monitor cancer development.

Peer reviewed and funded or endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 5,000 participants will be accrued for this study.

02

Conditions studied

  • Hereditary Multiple Melanoma
  • Melanoma (Skin)

Keywords

  • melanoma
  • hereditary multiple melanoma
  • recurrent melanoma
  • stage 0 melanoma
  • stage IV melanoma
  • stage IA melanoma
  • stage IB melanoma
  • stage IIA melanoma
  • stage IIB melanoma
  • stage IIC melanoma
  • stage IIIA melanoma
  • stage IIIB melanoma
  • stage IIIC melanoma
03

In context

Melanoma, Cutaneous Malignant

135 studies on the registry are indexed under Melanoma, Cutaneous Malignant; 18 are open to participants now.

This study's planned enrollment of 5,000 is above the median of 300 across 27 observational studies indexed under Melanoma, Cutaneous Malignant.

Browse Melanoma, Cutaneous Malignant studies →

Lead sponsor

Leeds Cancer Centre at St. James's University Hospital is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DISEASE CHARACTERISTICS:

  • Meets one of the following criteria:

    • Prior multiple primary melanomas

      • Histological samples available
    • Family history of melanoma, with melanoma in two first-degree relatives (e.g., cases of melanoma in both a mother and son or in two brothers but not in two cousins)
    • Family history of melanoma, where three or more individuals (of any relationship) have had melanoma

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
05

Study design

Enrollment
5,000 participants (estimated)
Patient registry
No

Interventions

  • Geneticgene expression analysis
  • Geneticmicroarray analysis
  • Geneticmolecular genetic technique
  • Geneticmutation analysis
  • Otherlaboratory biomarker analysis
  • Proceduremutation carrier screening
  • Procedurestudy of high risk factors
06

What researchers measure

Primary outcomes

  1. Predictive significance of melanoma susceptibility gene (MSG) mutations in the CDKN2A gene

  2. Susceptibility to other types of cancer as a feature of MSG mutations

  3. Risk of other types of cancers in mutation carriers

  4. Environmental exposures, in particular sun exposure, that modify risk of melanoma in MSG mutation carriers

07

Study locations

1 of 1 sites recruiting
  • Leeds Cancer Centre at St. James's University Hospital
    Leeds, England LS9 7TF, United Kingdom
    • Julia Newton Bishop, MD · Contact · 44-113-206-4668
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 1989 and a primary completion of Dec 2020. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2007
First posted
Mar 22, 2007
Start
Jan 1989
Primary completionEst.
Dec 2020
Last update
Aug 12, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00450593
Lead sponsor
Leeds Cancer Centre at St. James's University Hospital
First posted
Mar 22, 2007
Start date
Jan 1989
Primary completion
Dec 2020 (estimated)
Last update
Aug 12, 2013

Study contacts

Julia Newton Bishop, MD
study chair · Leeds Cancer Centre at St. James's University Hospital
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion